NCT01468584View on ClinicalTrials.gov

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Chronic Hepatitis C
Interventions
DRUG

MP-424 (generic name:Telaprevir)

750mg q8h for 12 weeks

DRUG

Ribavirin

400 - 1000 mg/day based on body weight for 24 weeks

DRUG

Peginterferon alfa-2b

1.5mcg/kg/week for 24 weeks

Trial Locations (1)

Unknown

Toranomon Hospital, Minato-ku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY